Results of single and double autografts for high-risk neuroblastoma patients.
Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factors for relapse were the presence of bone lesions at diagnosis, and a minor response or progressive disease at transplantation. In order to improve the outcome of these high-risk patients, we tested the feasibility of double autografts. To date, eight patients have been treated, and no treatment-related deaths were observed. Six remain in CR or with stable disease for 6 to 29 months. Although more cases and longer observation are needed to draw conclusions, these results are encouraging.
Kawa-Ha
K
K
Department of Pediatrics, Osaka Medical Centre, Japan.
Yumura-Yagi
K
K
Inoue
M
M
Park
D Y
DY
Okamura
T
T
Yasui
M
M
Oota
H
H
Sakata
N
N
Yoneda
M
M
Imura
K
K
D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000628:therapy*; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
D016179:Granulocyte Colony-Stimulating Factor